<!doctype html>
<html>
  <head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="chrome=1">
    <link rel="icon" href="images/RGicon.png">
    <link rel="stylesheet" href="stylesheets/styles-grey.css">
    <link rel="stylesheet" href="stylesheets/github-dark.css">
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.1/jquery.min.js"></script>
    <script src="javascripts/respond.js"></script>
    <!--[if lt IE 9]>
      <script src="//html5shiv.googlecode.com/svn/trunk/html5.js"></script>
    <![endif]-->
    <!--[if lt IE 8]>
    <link rel="stylesheet" href="stylesheets/ie.css">
    <![endif]-->
    <meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no">

<!--start mobile stuff-->
<style type="text/css">

   .mobileShow { display: none;}

   /* Smartphone Portrait and Landscape */

   @media only screen

   and (min-device-width : 320px)

   and (max-device-width : 480px){ .mobileShow { display: inline;}}

</style>
<style type="text/css">

   .mobileHide { display: inline;}

   /* Smartphone Portrait and Landscape */

   @media only screen

   and (min-device-width : 320px)

   and (max-device-width : 480px){  .mobileHide { display: none;}}

</style>
<!--End mobile stuff. From http://blog.hubspot.com/marketing/site-content-only-mobile-viewers-can-see-ht-->
  </head>
  <title>Impact of Medications on Myasthenis Gravis Patient Population at University Hospital</title>
  <body>


      <div id="header">
	<div class="mobileHide"> 
	<nav>
          <!--<li class="fork"><a href="rgummi1.github.io">Home</a></li>-->
          <li class="downloads"><a href="https://rgummi1.github.io/Impact%20of%20Meds%20on%20MG.pdf">PDF</a></li>
          <li class="title"><font size="2">| </font>  POSTER</li>
	  <li class="downloads"><a href="http://www.neurology.org/content/88/16_Supplement/P3.121.short">Neurology</a></li>
	  <li class="title">ABSTRACT AT AAN 2017:</li>
        </nav></div>
	<div class="mobileShow"><div align="right"><p style="margin-top: 10px;"><h3>AAN 2017: <a href="http://www.neurology.org/content/88/16_Supplement/P3.121.short">Neurology.org  </a>
       |  Poster: <a href="https://rgummi1.github.io/Impact%20of%20Meds%20on%20MG.pdf">PDF  </a></h3></p></div></div>
      </div><!-- end header -->

    <div class="wrapper">

      <section>
        <div id="title">
          <h1>IMPACT OF MEDICATIONS ON MYASTHENIA GRAVIS PATIENT POPULATION AT UNIVERSITY HOSPITAL</h1>
	  <h2><center>Rohit R. Gummi<sup><font size="-1">1</font></sup>, Natalie A. Kukulka<sup><font size="-1">1</font></sup>, Raghav Govindarajan MD<sup><font size="-1">2</font></sup><center></h2>
	  <h5> 1 University of Missouri School of Medicine<br>2 Department of Neurology, University of Missouri Hospital</h5>
          <p></p>
          <hr>
        </div>

<h1><a id="Abstract" class="anchor" href="#Abstract" aria-hidden="true"><span aria-hidden="true" class="octicon octicon-link"></span></a>ABSTRACT</h1>

<p>Background:<br>
Myasthenia Gravis (MG), a neuromuscular junction disorder is often treated alongside many concurrent diseases. Certain medications are contraindicated in patients with MG due to risk of exacerbation of symptoms, but are routinely prescribed thus putting patients at risk of exacerbation.
<br><br>Method:<br>
A retrospective chart review of MG patients at the University of Missouri Hospital was performed. This included 127 patients seen from 2011 to 2016. The demographics of the patients and causes of flare-ups were recorded. The total number of flare-ups for every patient that was prescribed a contraindicated medication after diagnosis with MG was compared to the total flare-ups for each MG patient that was not prescribed any of the contraindicated medications. Two sided t test was performed.
<br><br>Results:<br>
Average age was 61.9 years and average disease duration was 8.8 years. The patients had experienced 212 total flare-ups, with 106 requiring visits to the emergency room, and 141 requiring admission with an average duration of 6.2 days. Of the flare-ups, contraindicated medications played a part at 19%. Patients that were prescribed contraindicated medications also had a significantly higher number of flare-ups, with an average of 2.1, than patients not prescribed contraindicated medications, who had an average of .79 (p<0.01). Beta-blockers, specifically, were found to have a significant association with a higher number of flare-ups (p<0.01).
<br><br>Conclusion:<br>
Certain medications (some more than others) are common triggers of MG flare up. It is important to increase awareness among patients and physicians about these medications and subsequent risk for patients.

<br>
<h1><a id="References" class="anchor" href="#References" aria-hidden="true"><span aria-hidden="true" class="octicon octicon-link"></span></a></h1>
<br><br>
<h1>REFERENCES</h1>
<p><a href="https://bmcneurol.biomedcentral.com/articles/10.1186/1471-2377-10-46">Carr, Aisling S., et al.</a> "A systematic review of population based epidemiological studies in Myasthenia Gravis." BMC neurology 10.1 (2010): 1.</p>

<p><a href="http://www.jci.org/articles/view/29894">Conti-Fine, Bianca M., Monica Milani, and Henry J. Kaminski.</a> "Myasthenia gravis: past, present, and future." The Journal of clinical investigation 116.11 (2006): 2843-2854.</p>

<p><a href="http://accessmedicine.mhmedical.com/content.aspx?bookid=1130&sectionid=79756727">Drachman, Daniel B., and Anthony A. Amato.</a> "Myasthenia Gravis and Other Diseases of the Neuromuscular Junction." Harrison's Principles of Internal Medicine, 19e. Eds. Dennis Kasper, et al. New York, NY: McGraw-Hill, 2015. n. pag. AccessMedicine. Web.</p>
<p><a href="http://www.myasthenia.org/LivingwithMG/DrugstoAvoid.aspx">"Drugs to Avoid."</a> Myasthenia Gravis Foundation of America, INC. Myasthenia Gravis Foundation of America, INC., n.d. Web. 22 Aug. 2016.<a href="http://www.myasthenia.org/LivingwithMG/DrugstoAvoid.aspx"></a></p>

<p><a href="http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(09)70063-8/abstract">Meriggioli, Matthew N., and Donald B. Sanders.</a> "Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity." The Lancet Neurology 8.5 (2009): 475-490.</p>
<a href="#top">Top</a>      
</section>
    </div>
<script>
	  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
	  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
	  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
	  })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');
	
	  ga('create', 'UA-10254419-2', 'auto');
	  ga('send', 'pageview');

	</script>
</body>
</html>
